CAR-巨噬细胞在恶性血液病中的研究进展  

Research progress of CAR-macrophages in malignant hematological diseases

作　　者：郑如冰 肖毅[1] Zheng Rubing;Xiao Yi(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液科,武汉430030

出　　处：《中华血液学杂志》2024年第4期413-416,共4页Chinese Journal of Hematology

基　　金：国家自然科学基金面上项目(81873444、82070213、82370196)。

摘　　要：本文回顾了嵌合抗原受体巨噬细胞(chimeric antigen receptor macrophage,CAR-M)疗法的发展历程,探讨了其在恶性血液系统疾病中的应用进展,介绍了CAR-M相关的临床试验,分析了CAR-M疗法在临床应用中面临的优势与挑战,并对其在未来治疗恶性血液病的应用前景进行了展望。This article reviews the development history of chimeric antigen receptor macrophage(CAR-M)therapy,discusses its application in malignant hematologic diseases,introduces related clinical trials,analyzes the advantages and challenges faced by CAR-M therapy in clinical application,and looks forward to its future use in the treatment of malignant hematologic diseases.

关 键 词：恶性血液病 嵌合抗原受体 巨噬细胞 CAR 临床试验 恶性血液系统疾病 临床应用 优势与挑战 

分 类 号：R733[医药卫生—肿瘤]